With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.